Skip to main content
. Author manuscript; available in PMC: 2017 Oct 28.
Published in final edited form as: J Control Release. 2016 Jun 8;240:489–503. doi: 10.1016/j.jconrel.2016.06.012

Figure 5.

Figure 5

A) Pharmacokinetics of cytarabine and daunorubicin in the plasma after i.v. administration of CPX-351 (12:5.3 mg/kg) or free-drug cocktail (600:9 mg/kg) to CD-1 nude mice. The insert shows that CPX-351 maintained molar drug ratios of co-loaded cytarabine and daunorubicin between 5:1 and 9:1 over 24 h during the blood circulation. These ratios had been determined to be the most synergistic ratios in vitro; B) Survival curves of CD-1 nude mice bearing WEHI-3B monomyelocytic leukemia tumor treated with saline, maximum tolerated dose (MTD) of free cytarabine and daunorubicin cocktails (300:4.5 mg/kg), ratio-matched free cytarabine and daunorubicin cocktails (12:5.3 mg/kg) or CPX-351 (12: 5.3 mg/kg). The figures are permitted and reproduced from Tardi et al.2009 [38].